Pharmacokinetics of Antiretroviral Drug Varies With Formulation in the Target Population of Children With HIV-1-Reference-Cited by-同舟云学术

Pharmacokinetics of Antiretroviral Drug Varies With Formulation in the Target Population of Children With HIV-1

Published:2011-12-21 Issue:2 Volume:91 Page:272-280
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Kasirye P,Kendall L,Adkison K K,Tumusiime C,Ssenyonga M,Bakeera-Kitaka S,Nahirya-Ntege P,Mhute T,Kekitiinwa A,Snowden W,Burger D M,Gibb D M,Walker A S

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference35 articles.

1. Lamivudine in Children with Human Immunodeficiency Virus Infection: A Phase I/II Study

2. A Model-Based Approach to Dose Selection in Early Pediatric Development

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Model‐Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed‐Dose Combination Approval in Children Living with HIV‐1;The Journal of Clinical Pharmacology;2024-09-05

2. Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1;Infectious Diseases and Therapy;2024-07-04

3. Pharmacokinetic Drug-Drug Interactions Involving Antiretroviral Agents: An Update;Current Drug Metabolism;2023-07

4. How to select the initial dose for a pediatric study?;Journal of Biopharmaceutical Statistics;2022-12-08

5. Pharmacokinetics and safety of the abacavir/lamivudine/lopinavir/ritonavir fixed-dose granule formulation (4-in-1) in neonates;JAIDS Journal of Acquired Immune Deficiency Syndromes;2021-12-02